Table 2.
Patient characteristics and laboratory measurements
| n (%), median [IQR], or mean {SD} | |
|---|---|
| Patient characteristics | |
| Age (years) | 57 {12} |
| Gender: male/female | 12 (80)/3 (20) |
| Weight (kg) | 79 {17} |
| Height (cm) | 177 {8} |
| 28-day mortality | 11 (73.3) |
| SAPS II | 69 {14} |
| Norepinephrine dosage (mg/h) at start | 1.8 [1.1–2.7] |
| Norepinephrine dosage (mg/h) after 12 h | 1.9 [0.7–3.3] |
| Vasopressin dosage (IE/h) at start | 1.0 [0–2.0] |
| Vasopressin dosage (IE/h) after 12 h | 1.5 [0–2.0] |
| Kidney replacement therapy | |
| Dialyzer | Fresenius MultiFiltrate circuit (MultiFiltrate Ultraflux® AV 1000S) |
| CVVHD (CiCa®)/CVVHDF (MultiBic®, post-dilution) | 11 (73.3)/5 (26.7) |
| Blood flow (ml/min) | 100 [100–225] |
| CVVHD | 100 [100–150] |
| CVVHDF | 255 [225–295] |
| Laboratory parameters before initiation of CytoSorb® | |
| IL-6 (pg/ml) | 1136 [415–4504] |
| C-reactive protein (mg/dl) | 10.1 [5.7–26.8] |
| Creatinine (mg/dl) | 1.9 [1.3–2.6] |
| Urea (mg/dl) | 65 {38} |
| Procalcitonin (ng/ml) | 10.1 [6.1–103] |
| Bilirubin (mg/dl) | 3.3 [2.2–6.2] |
| Lactate (mmol/l) | 4.8 [2.3–13.0] |
IQR interquartile range, SD standard deviation, SAPS II Simplified Acute Physiology Score, CVVHD(F) continuous veno-venous hemodialysis/hemodiafiltration